User login
Key clinical point: Patients with multiple sclerosis (MS) are at an increased risk for cancer than the general population.
Major finding: Compared with the general population, patients with MS were at a significantly higher risk for cancer (hazard ratio [HR], 1.36; 95% CI, 1.29-1.43), particularly prostate cancer (HR, 2.08; 95% CI, 1.68-2.58), colorectal and anal cancer (HR, 1.35; 95% CI, 1.16-1.58), and trachea bronchus and lung cancer (HR, 2.36; 95% CI, 1.96-2.84).
Study details: This population-based matched-cohort study included 95,474 patients with MS matched with 95,474 individuals from the general population.
Disclosures: This study was sponsored by Merck Healthcare KGaA. Four authors including the lead author reported being employees of the Bordeaux PharmacoEpi, and the remaining authors reported being full-time employees of Merck Healthcare KGaA, Darmstadt, Germany. The lead author reported receiving speaker fees from Biogen.
Source: Bosco-Lévy P et al. Eur J Neurol. 2021 Dec 22. doi: 10.1111/ene.15226.
Key clinical point: Patients with multiple sclerosis (MS) are at an increased risk for cancer than the general population.
Major finding: Compared with the general population, patients with MS were at a significantly higher risk for cancer (hazard ratio [HR], 1.36; 95% CI, 1.29-1.43), particularly prostate cancer (HR, 2.08; 95% CI, 1.68-2.58), colorectal and anal cancer (HR, 1.35; 95% CI, 1.16-1.58), and trachea bronchus and lung cancer (HR, 2.36; 95% CI, 1.96-2.84).
Study details: This population-based matched-cohort study included 95,474 patients with MS matched with 95,474 individuals from the general population.
Disclosures: This study was sponsored by Merck Healthcare KGaA. Four authors including the lead author reported being employees of the Bordeaux PharmacoEpi, and the remaining authors reported being full-time employees of Merck Healthcare KGaA, Darmstadt, Germany. The lead author reported receiving speaker fees from Biogen.
Source: Bosco-Lévy P et al. Eur J Neurol. 2021 Dec 22. doi: 10.1111/ene.15226.
Key clinical point: Patients with multiple sclerosis (MS) are at an increased risk for cancer than the general population.
Major finding: Compared with the general population, patients with MS were at a significantly higher risk for cancer (hazard ratio [HR], 1.36; 95% CI, 1.29-1.43), particularly prostate cancer (HR, 2.08; 95% CI, 1.68-2.58), colorectal and anal cancer (HR, 1.35; 95% CI, 1.16-1.58), and trachea bronchus and lung cancer (HR, 2.36; 95% CI, 1.96-2.84).
Study details: This population-based matched-cohort study included 95,474 patients with MS matched with 95,474 individuals from the general population.
Disclosures: This study was sponsored by Merck Healthcare KGaA. Four authors including the lead author reported being employees of the Bordeaux PharmacoEpi, and the remaining authors reported being full-time employees of Merck Healthcare KGaA, Darmstadt, Germany. The lead author reported receiving speaker fees from Biogen.
Source: Bosco-Lévy P et al. Eur J Neurol. 2021 Dec 22. doi: 10.1111/ene.15226.